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The trigger initiating an autoimmune response against melanocytes in vitiligo remains unclear. Patients frequently
experience stress to the skin prior to depigmentation. 4-tertiary butyl phenol (4-TBP) was used as a model com-
pound to study the effects of stress on melanocytes. Heat shock protein (HSP)70 generated and secreted in
response to 4-TBP was quantiﬁed. The protective potential of stress proteins generated following 4-TBP exposure
was examined. It was studied whether HSP70 favors dendritic cell (DC) effector functions as well. Melanocytes were
more sensitive to 4-TBP than ﬁbroblasts, and HSP70 generated in response to 4-TBP exposure was partially
released into the medium by immortalized vitiligo melanocyte cell line PIG3V. Stress protein HSP70 in turn induced
membrane tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and activation of DC ef-
fector functions towards stressed melanocytes. Melanocytes exposed to 4-TBP demonstrated elevated TRAIL
death receptor expression. DC effector functions were partially inhibited by blocking antibodies to TRAIL. TRAIL
expression and inﬁltration by CD11cþ cells was abundant in perilesional vitiligo skin. Stressed melanocytes may
mediate DC activation through release of HSP70, and DC effector functions appear to play a previously unappre-
ciated role in progressive vitiligo.
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Vitiligo is an acquired skin disorder, involving an autoim-
mune response against melanocytes (Boissy, 2001; Le
Poole et al, 2004). It remains to be explained as to what
triggers the autoimmune response to melanocytes. Patients
frequently refer to skin trauma as an initiating factor for their
disease. Melanocyte overexposure to ultraviolet rays may
cause deregulation of melanization and/or of mitosis, in-
ducing a stress response in the pigment cell (Jean et al,
2001). Sites of mechanical stress will express elevated lev-
els of stress proteins (Kippenberger et al, 1999). Burns and
cuts have been documented as initiation sites for progres-
sive depigmentation, and the Koebner phenomenon is often
observed in vitiligo patients (Le Poole and Boissy, 1997).
Finally, in individuals sensitive to bleaching phenols, expo-
sure to phenolic compounds in the workplace can cause
what has been coined ‘‘occupational vitiligo’’ (Boissy and
Manga, 2004). Skin trauma leads to oxidative stress, and
accumulation of H2O2 has been observed in vitiligo lesional
skin (Schallreuter et al, 1999). These conditions will induce
expression of stress proteins including heat shock protein
(HSP)70 and will enhance the activity of anti-oxidative en-
zymes to protect skin cell viability (Currie and Tanguay,
1991; Calabrese et al, 2001; Renis et al, 2003). In this study,
4-tertiary butyl phenol (4-TBP) was chosen as a model
compound to address stress protein expression and its in-
volvement in initiating an autoimmune response to me-
lanocytes by dendritic cells (DC).
It has been hypothesized that bleaching compound 4-
TBP can serve as an alternative substrate for tyrosinase,
which would explain its inhibitory effect on melanin synthe-
sis (Yang and Boissy, 1999). Competitive inhibition of tyros-
inase, the rate-limiting enzyme involved in melanogenesis,
occurs at low 4-TBP concentrations. Conversion of 4-TBP
into semiquinone free radicals can contribute to cellular
stress (Boissy and Manga, 2004). Cytotoxic responses oc-
cur at a higher concentration of 4-TBP and are independent
of the degree of pigmentation of melanocytes (Yang et al,
2000). Expression of the A2b receptor for adenosine was
enhanced in response to 4-TBP, and expression of this re-
ceptor may sensitize melanocytes to apoptosis (Le Poole
et al, 1999).
Stressed cells are characterized by elevated expression
of stress proteins. Stress proteins include the HSP family
upregulated in response to elevated environmental tem-
peratures and other forms of stress. Stress proteins are
evolutionarily very well conserved, and they function as
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chaperone molecules protecting cellular proteins from pre-
mature degradation by supporting proper protein folding
(Houry, 2001). Cells with elevated levels of stress proteins
are protected from the consequences of subsequent stress
episodes (Mestril and Dillmann, 1995).
Contrary to the cytoprotective effect of intracellular
stress proteins, once released into the extracellular milieu
stress proteins can induce an immune response to the very
cells from which they were derived. Stress proteins are
immunogenic and were shown to serve as antigens in cer-
tain autoimmune diseases, which is best explained by the
extensive homology observed between human and bacte-
rial stress proteins or ‘‘antigen mimicry’’ (Bell, 1996; Xu,
2003).
Besides serving as antigens, stress proteins also en-
hance an immune response by inducing phagocytosis and
processing of chaperoned antigens by DC (Noessner et al,
2002). Consequently, stress proteins have been included as
adjuvants in tumor vaccines (Srivastava and Amato, 2001).
Recently, it was reported that DC can specifically kill
tumor cells whereas surrounding, healthy cells are left un-
touched (Janjic et al, 2002; Lu et al, 2002). DC-mediated
killing was found to be mediated by expression of tumor
necrosis factor (TNF) family members on the DC surface,
accompanied by the expression of the appropriate recep-
tors by tumor cells (Lu et al, 2002). Healthy control cells do
not express the same levels of such receptors, and are thus
protected from DC-mediated killing (Lu et al, 2002). The
hypothesis under study is that DC are equally capable of
killing stressed melanocytes to initiate an autoimmune re-
sponse resulting in progressive depigmentation of the skin.
The direct effects of 4-TBP exposure on cell viability of
control and vitiligo-derived melanocytes was measured. In-
duction of HSP70 induction was assessed, and expression
of HSP70 was artificially elevated by adenoviral overex-
pression to evaluate its cytoprotective effect. DC exposed
to activating stress proteins or activated by interferon-g
(IFN-g) were reacted with stressed and unstressed me-
lanocytes, and resulting melanocyte death was measured.
The cytotoxicity observed was correlated to membrane ex-
pression of TNF family members by DC, and to corre-
sponding death receptors on stressed melanocytes. Finally,
the results were correlated to observations in vitiligo skin by
immunohistology. These studies were performed to evalu-
ate a possible role of stress proteins and of DC in initiating
depigmentation.
Results
Viability of cells in the presence and absence of 4-
TBP In Fig 1, the viability of normal melanocyte culture
Mc0009 P12, as well as immortalized cell lines PIG1 and
PIG3V, and normal fibroblast culture Ff9929 P7 was shown
in the presence or absence of 4-TBP. At relatively low con-
centrations of 4-TBP (250 mM), the viability of both im-
mortalized cell lines, PIG1 and particularly PIG3V, was
significantly reduced (to 59.1% and 37.5%, respectively).
The difference in viability among PIG1 and PIG3V cells was
not considered significant at p¼0.11 in a t test. The viability
of primary fibroblast and melanocyte cell cultures was not
affected at 250 mM of 4-TBP. Overall, fibroblasts were less
sensitive to 4-TBP than melanocytes and a significant re-
duction in fibroblast viability was noted only at 1 mM of 4-
TBP (p¼0.001).
Induction of HSP70 expression by 4-TBP Expression of
HSP70 by immortalized melanocytes cultured in the pres-
ence or absence of 4-TBP is shown in Fig 2A. It can be
observed that the level of intracellular HSP70 increased up
to 6.1-fold in PIG1 control melanocytes and 5.2-fold in
PIG3V vitiligo melanocytes in the presence of 4-TBP when
compared with untreated cells. Interestingly, a 3.3-fold in-
crease in the release of HSP70 was also observed for PIG3V
vitiligo melanocytes following treatment with 500 mM 4-TBP
as shown in Fig 2B. Moreover, a 5.3-fold increase in the
HSP70 content of the medium was noted for PIG3V versus
PIG1 melanocytes, further supporting that the vitiligo me-
lanocytes secrete a relatively larger proportion of the stress
proteins.
Protection from 4-TBP exposure by adenoviral overex-
pression of HSP27 or HSP70 Melanocytes overexpress-
ing HSP27 or HSP70 were treated with 4-TBP in the range
of 0–1000 mM for 72 h prior to measuring cell viability.
Adenoviral overexpression of HSP70 by melanocytes fol-
lowing adenoviral infection was confirmed by western blot-
ting as shown in Fig 3. A 3.7-fold increase in HSP70 content
was demonstrated only for cells exposed to AdHSP70, with
no increase observed following exposure to other adeno-
viruses. Western blot analysis of HSP27 expression re-
vealed that the stress of the adenoviral infection procedure
per se upregulated HSP27 expression to a similar extent
in all three samples compared with untreated cells (not
shown). Similar results were observed for PIG1 cells (not
shown). As shown in Fig 4, it was observed that adenoviral
overexpression of either HSP27 or HSP70 did not ade-
Figure1
Reduced viability of skin cells in the presence of 4-tertiary butyl
phenol (4-TBP). Cultured melanocytes Mc0009 P12, fibroblasts
Ff9929 P7, immortalized normal PIG1, and vitiligo PIG3V melanocyte
cell lines were subjected to 4-TBP exposure at different concentrations
for 72 h. Cell viability (  SEM) was measured in a just another method
(JAM) assay. At 250 mM of 4-TBP, both immortalized cell lines expe-
rienced significantly reduced viability compared with untreated cells
(p¼0.013 or 0.009 for PIG1 cells and PIG3V cells, respectively). Rep-
resentative experiment of three performed.
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quately protect the cells from 4-TBP-induced cell death at
any of the concentrations tested. The same results were
obtained when testing PIG3V, demonstrating that a lack of
protection by stress proteins also occurred in vitiligo cells
(results not shown).
DC-mediated killing of melanocytes In Fig 5, the cyto-
toxicity of DC toward normal melanocytes and immortalized
PIG1 cells is shown. Normal melanocyte culture Mf0201 P5
was pretreated with or without 250 mM 4-TBP for 24 h. DC
were either immature DC or cells activated in the presence
of 1 mg per mL of HSP 27, 60, and 70 for 48 h. Pre-treatment
of DC with HSP clearly activated the cytotoxic ability of the
DC, increasing cell death for both target cell types, most
notably for melanocytes exposed to 4-TBP (from 7.4% to
65.2%). Melanocytes cultured in the presence of 4-TBP
were sensitized to killing by HSP-activated DC, increasing
the cytotoxicity 5.8-fold when chromium release was meas-
ured after 48 h compared with cells not treated with the
bleaching agent.
Membrane expression of TNF family molecules and re-
ceptors In Fig 6, upregulation of TNF-related apoptosis-
inducing ligand (TRAIL) receptors 1 and 2 (TRAILR1 and
TRAILR2), and TNF receptors 1 and 2 (TNFR1 and TNFR2)
was shown after exposing melanocytes to 4-TBP. The mean
fluorescence intensities were increased to 8.5-, 6.3-, 1.8-,
and 2.9-fold over untreated cells, respectively, in the pres-
ence of 4-TBP, suggesting a potential role in sensitizing
melanocytes to DC-mediated killing. Meanwhile, Fas ex-
pression was reduced to 0.6-fold at 250 mM 4-TBP. Fluo-
rescence activated cell sorting (FACS) histograms also
show upregulation of the HSP receptor CD91 (1.7-fold) and
more so of tyrosinase-related protein (TRP)-1 (2.2-fold) at
Figure 2
Induction of heat shock protein (HSP)70 expression by 4-tertiary
butyl phenol (4-TBP). Immortalized normal control melanocytes PIG1
and vitiligo PIG3V melanocytes were subjected to 4-TBP exposure for
72 h, followed by analysis of (A) intracellular HSP70 expression and (B)
HSP70 within the media by ELISA and expressed as HSP70 content
(  SD). Intracellular expression over untreated control was increased
significantly for PIG1 cells at 125 mM of 4-TBP and higher (p¼ 0.006)
and for PIG3V at 62.5 mM and higher (p¼ 0.016). A significant increase
in HSP70 within the media following 4-TBP exposure was noted only
for PIG3V cells at 250 (p¼0.030) and 500 mM 4-TBP (p¼ 0.013).
Figure3
Adenoviral overexpression of heat shock proteins (HSP). Overex-
pression of HSP70i by normal human melanocytes (Mc0009 P13)
shown by western blotting following infection with adenovirus, as
compared with b-actin content. Relative band intensities support a 3.7-
fold increase following adenoviral infection AdHSP70i.
Figure4
Lack of protection from apoptosis by heat shock proteins (HSP).
Cell viability was measured by trypan blue exclusion of transfected
Mc0009 P12 melanocytes following exposure to 4-tertiary butyl phenol
(4-TBP) for 72 h. Overexpression of either HSP27 or HSP70 did not
protect melanocytes from 4-TBP-induced cell death at any of the con-
centrations tested.
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125 mM 4-TBP. Finally, suppression of stem cell factor re-
ceptor c-KIT was observed for both 4-TBP concentrations,
reducing expression to 0.3-fold at 250 mM 4-TBP.
A 2.2-fold increase in the mean fluorescence intensity for
TRAIL expression by IFN-g treated DC was shown in Fig 7.
TNF and Fas ligand (FasL) expressions were not upregu-
lated by IFN-g on the DC membrane. Similar upregulation of
TRAIL expression was observed by DC exposed to a cock-
tail of HSP 27, 60, and 70 (not shown). Histograms repre-
senting TRAIL expression in the absence and presence of
4-TBP demonstrate that 4-TBP exposure cannot directly
mediate TRAIL upregulation by DC (not shown).
Antibody-mediated blocking of TRAIL activity Me-
lanocytes were exposed to soluble killer TRAIL or to acti-
vated DC, in the presence and or absence of TRAIL-reactive
antibodies as shown in Fig 8. Killer TRAIL was cytotoxic for
up to 37% of PIG1 melanocytes, and this effect was ne-
gated in the presence of the anti-TRAIL Ab RIK-2, which
restored viability to 95%. More killing of PIG1 cells was
observed in the presence of activated DC (53%) than by
soluble killer TRAIL, and this response was only partially
inhibited by RIK-2, restoring viability to 62%. This suggests
Figure 5
Dendritic cell (DC)-mediated killing of stressed melanocytes. PIG1
immortalized melanocytes or normal melanocytes (Mf0201 P5) pre-
treated without or with 250 mM 4-tertiary butyl phenol (4-TBP) for 24 h
were exposed to immature or heat shock protein-(HSP-) activated DC
at an effector:target ratio of 5:1. Cytotoxicity was measured by chro-
mium release at 48 h. DC activated by a cocktail of endotoxin-free HSP
27, 60, and 70 (1 mg per mL for 48 h) were more capable than immature
DC of killing 4-TBP-treated melanocyte targets (p¼0.036) and were
more effective against 4-TBP-exposed cells than against untreated
targets (p¼0.043).
Figure 6
Melanocyte marker expression modified of 4-tertiary butyl phenol (4-TBP). Normal melanocytes (Mc0009 P8) were exposed to 0 (Rows 1 and
4), 125 (Rows 2 and 5), or 250 (Rows 3 and 6) mM 4-TBP for 72 h, followed by immunostaining and fluorescence activated cell sorting analysis of
expression of tumor necrosis factor-(TNF-) related apoptosis-inducing ligand (TRAIL) receptor (R)1, TRAILR2, TNFR1, TNFR2, Fas, CD91, tyros-
inase-related protein (TRP-1), and c-KIT. Upregulation of TRAIL and TNF receptors as well as CD91 and TRP-1 is accompanied by reduced
expression of Fas and c-KIT in response to 4-TBP.
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that other mechanisms in addition to TRAIL contribute to
melanocyte killing by DC.
DC inﬁltration of vitiligo skin An increase in the number
of infiltrating CD11cþ DC was observed in perilesional skin
(78.03 cells per mm epidermis) when compared with with
non-lesional skin from the same patients (37.35 cells per
mm epidermis). This difference was found to be significant
in a one-tailed paired t test (n¼ 4; p¼ 0.026). It should be
noted that it was not known whether these patients were
exposed to bleaching phenols prior to the onset of their
vitiligo. In Figs 9A and B, perilesional skin sections were
shown with representative examples of focal infiltration
CD11cþ and TRAILþ cells, respectively. In Fig 9C, co-
detection of CD11c (red) and TRAIL (blue) is depicted. Ex-
amples of cells co-expressing both markers are highlighted
by purple arrows. These results suggested that TRAIL-ex-
pressing DC specifically infiltrate perilesional skin of vitiligo
patients with active disease. Expression of TRAILR1 was
confined to cells in the basal layer of the epidermis directly
adjacent to the border of the lesion. An example of gp100þ
melanocytes (blue) expressing TRAILR1 (red) is shown in
Fig 9D. Expression was typically observed in a region span-
ning up to ten melanocytes directly adjacent to the lesion. It
is possible that some of the TRAILR1 expression observed
should be assigned to interspersing keratinocytes; however,
keratinocytes are expected to be less affected by TRAILR1
expression than melanocytes because of their high turnover
rate. Expression of TRAILR2 was not observed in vitiligo
perilesional skin (not shown).
Discussion
Topically applied phenolic compounds, including 4-TBP,
can selectively damage melanocytes in the basal layer of
the epidermis and can lead to progressive skin depigmen-
tation in some individuals. At higher concentrations (4100
mM), 4-TBP is cytotoxic to melanocytes more so than to
keratinocytes (Yang et al, 2000). PIG3V vitiligo melanocytes
showed a tendency to be more sensitive to 4-TBP than
control melanocyte cell line PIG1. The putative cytoprotec-
tive effect of stress proteins was inadequate to prevent cell
death in either cell line as adenoviral overexpression of ei-
ther HSP27 or HSP70 failed to protect PIG1 or PIG3V me-
lanocytes from 4-TBP-induced cell death. Such a lack of
protection can possibly be explained by inadequate acti-
vation of antioxidant enzymes, as supported by the thera-
peutic potential of pseudocatalase in vitiligo (Schallreuter
et al, 1999). Both the PIG1 and PIG3V cell lines upregulated
HSP70 expression in response to 4-TBP, and vitiligo me-
lanocytes released a larger proportion of HSP70 into the
media. HSP70 released into the medium is likely the result
of active secretion by vitiligo melanocytes, as (a) increased
release by vitiligo melanocytes over control melanocytes
was observed at non-toxic 4-TBP concentrations and (b)
HSP70 release was increased by vitiligo melanocytes but
not control melanocytes at 500 mM 4-TBP, a concentration
that was equally cytotoxic to both cell types. It is of interest
that this observation is paralleled by less homogeneous
HSP70 immunostaining in perilesional epidermis from three
vitiligo patients than in non-lesional skin from the same in-
dividuals (not shown), suggesting that release of HSP70
may occur from progressive vitiligo epidermis in vivo.
Release of HSP70 from viable cells was reported for the
constitutive as well as the inducible form of HSP70 (Barreto
et al, 2003; Broquet et al, 2003). The mechanism reportedly
involves the release of membrane-bound HSP70 from lipid
rafts (Broquet et al, 2003). For the constitutive form of
HSP70, it was demonstrated that release was inducible by a
Figure 7
Dendritic cell (DC) tumor necrosis factor- (TNF-) related apoptosis-
inducing ligand (TRAIL) expression enhanced by interferon-c (IFN-
c). Fluorescence activated cell sorting (FACS) analysis of DC untreated
or activated by exposure to IFN-g (1000 U per mL for 48 h) revealing
enhanced expression of TRAIL, but not Fas or TNF-a. Mean fluores-
cence intensities  coefficient of variation (CV) are shown.
Figure 8
Killing of immortalized melanocytes by soluble tumor necrosis
factor related apoptosis-inducing ligand (TRAIL). Tritium-labeled
PIG1 melanocytes were cultured in the presence of 200 ng per mL
soluble TRAIL or interferon-g (IFN-g) activated dendritic cells (DC)
(DCIFN), in the presence or absence of 5 mg per mL blocking anti-
body to TRAIL (AbTRAIL) for 72 h. Cell viability (  SD) was measured.
t tests indicated that melanocyte viability was significantly reduced by
TRAIL (p¼0.011) and significantly restored by anti-TRAIL antibody
(p¼ 0.018). The viability of PIG1 melanocytes was also significantly
reduced in the presence of DC (p¼ 0.0002). Partial retrieval of me-
lanocyte viability observed for DC-exposed melanocytes incubated in
the presence of the blocking Ab to TRAIL was also significant
(p¼ 0.034).
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variety of cytokines, most notably IFN-g (Barreto et al,
2003). The latter cytokine is generated in perilesional vitiligo
skin by infiltrating T cells (Le Poole et al, 2003; Wankowicz-
Kalinska et al, 2003).
Exposure to 4-TBP enhanced HSP70 expression by me-
lanocytes. Stress proteins occasionally secreted by viable
cells have been coined ‘‘chaperokines’’, reflecting the inter-
cellular effects commonly assigned to cytokines while
chaperoning peptides specific to the cell type from which
they were derived (Asea et al, 2000; Asea, 2003). This may
reflect an early phase of an immune response, as HSP70
was shown to induce secretion of primary cytokines IL-1,
IL-6, and TNF-a by monocytes/macrophages in a C14-de-
pendent fashion (Asea et al, 2000). It was previously shown
that melanocytes can generate primary cytokines as well
(Kruger-Krasagakes et al, 1995). As the FACS data shown in
Fig 6 support upregulated expression of HSP receptor
CD91 by melanocytes in response to 4-TBP, cytokine re-
lease from melanocytes may be indirectly increased follow-
ing 4-TBP exposure.
Following induction of an innate immune response,
stress proteins induce antigen-specific immunity by en-
hancing antigen uptake and processing by DC (Noessner
et al, 2002). In this study it was demonstrated that HSP
likewise induce DC effector functions. Similarly, HSP70 was
shown to enhance natural killer cell cytolytic activity (Mu-
lthoff et al, 1999). Results obtained with purified HSP must
be considered with some caution as commercial prepara-
tions continue to improve in purity, and the effects of HSP
on DC activation have been assigned to contaminants (in
particular lipopolysaccharide) by others (Bausinger et al,
2002). Commercially obtained purified low-endotoxin HSP
used in this study containedo50 EU per mg endotoxin. In
accordance with earlier reports, IFN-g was also shown to
activate DC effector functions (Fanger et al, 1999).
Cell surface expression of different TNF family molecules
has been implicated in DC effector functions (Lu et al, 2002).
Our results indicate that TRAIL is a major player in DC-
mediated cytotoxicity toward stressed melanocytes. This is
supported by previous reports of a crucial role for TRAIL in
DC-mediated killing of tumor cells (Fanger et al, 1999). Here,
DC activation was accompanied by enhanced expression of
TRAIL, but not of TNF or FasL by DC. Direct exposure to 4-
TBP did not induce TRAIL expression by DC (not shown).
Exposure of target melanocytes to 4-TBP did induce ex-
pression of TRAIL receptors as well as TNF-a receptors, but
not Fas. Enhanced receptor expression sensitizes me-
lanocytes to DC-mediated killing, as observed in cytotox-
Figure 9
Support for in vivo involvement of dendritic cell-mediated melanocyte killing in vitiligo. Immunostaining of perilesional vitiligo skin with
antibodies to CD11c (A), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (B), or both, with CD11c in red and TRAIL in blue (C), and
immuno double staining for melanocyte marker gp100 (blue) and TRAILR1 (red) (D). Results are representative of frozen sections analyzed from four
different patients. Purple arrows: examples of double-stained cells. Scale bar¼70 mM (A), 40 mM (B), 20 mM (C), and 40 mM (D).
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icity assays. TRAIL expressing DC could be replaced at
least in part by soluble killer TRAIL, supporting a contribu-
tion for TRAIL in melanocyte cytotoxicity. DC-mediated
cytotoxicity is commonly thought to be restricted to tumor
cells, whereas normal tissue cells remain unaffected. It has
been shown, however, that certain preparations of soluble
TRAIL are less selective toward malignantly transformed
cells (Qin et al, 2001).
Here it was shown, that TRAIL expressing DC can like-
wise be cytotoxic towards stressed yet untransformed tis-
sue cells. As 4-TBP selectively targets melanocytes, it is
likely that 4-TBP-induced epidermal stress can lead to se-
lective killing of epidermal melanocytes by DC. This may
instigate a systemic autoimmune response to melanocytes
when the same DC return to draining lymph nodes, recruit-
ing melanocyte-reactive cytotoxic T cells to the skin. Our
own preliminary data indicate that HSP-treated DC are
more efficient at inducing mixed lymphocyte reaction (MLR)
responses than untreated, immature DC (unpublished). The
T cell infiltrate resulting from such an interaction may in turn
be more effective as stress proteins can ultimately enhance
T cell cytotoxicity and induce autoimmunity in vivo (Millar
et al, 2003). Taken together, our results indicate that DC-
mediated killing of stressed epidermal melanocytes may
represent an early and previously unrecognized event con-
tributing to progressive skin depigmentation in vitiligo.
Materials and Methods
Cell culture Normal human melanocytes were cultured in M154
medium with human melanocyte growth supplements (HMGS;
Cascade Biologicals, Portland, Oregon) and with 100 IU per mL
penicillin, 100 mg per mL streptomycin, and 250 ng per mL amp-
hotericinB (Invitrogen, Carlsbad, California).
Immortalized human melanocyte cell lines PIG1 (control cell
line) and PIG3V (vitiligo cell line) were similarly cultured in M154
with HMGS. These cell lines were immortalized by retroviral intro-
duction of HPV16 E6 and E7 genes (Le Poole et al, 2000).
Normal human dermal fibroblasts were cultured in DMEM with
10% heat-inactivated fetal bovine serum (FBS), 100 IU per mL
penicillin, 100 mg per mL streptomycin, and 250 ng per mL amp-
hotericinB (Invitrogen).
Human adherent monocyte-derived DC were generated from
leukapheresed peripheral blood mononuclear cells, and cultured
in AIMV medium (Invitrogen) in the presence of 25 ng per mL IL-4
(R&D Systems, Minneapolis, Minnesota) and 100 ng per mL gran-
ulocyte macrophage-colony stimulating factor (Immunex, Seattle,
Washington) for 7 d. DC were activated in the presence of 1 mg per
mL HSP27, HSP60, and HSP70 each (Stressgen, Victoria, British
Columbia, Canada) or 1000 U per mL of human IFN-g (R&D Sys-
tems) for the last 48 h of culture.
Viability testing Cultured cells were treated with 4-TBP in con-
centrations ranging from 0 to 1000 mM for 72 h. The viability of the
resulting cell cultures was assessed by trypan blue exclusion, and
expressed as a percentage of the total number of cells observed.
Alternatively, cells were plated at 10,000 cells per well of a 96-well
plate, labeled with 1 mCi per well of 3H-thymidine (Amersham Bio-
sciences, Piscataway, New Jersey), and treated in the presence
and absence of 4-TBP for 72 h. The plates were then harvested in a
Packard Filtermate 196-cell harvester (Minneapolis, Minnesota)
and tritium incorporated in the DNA of viable cells was counted in a
Packard Top Count microplate scintillation and luminescence
counter.
HSP70 detection Western blotting to assess the levels of stress
proteins was performed by denaturing polyacrylamide gel elect-
rophoresis of cell homogenates in a 10% gel, and subsequent
indirect immunostaining of the resulting gel blot by anti-human
HSP70i antibody SPA-810 (Stressgen Biotechnologies, San Diego,
California) as well as by C4 anti-actin antibody (ICN Biomedicals,
Aurora, Ohio), followed by alkaline phosphatase-labeled IgG1-spe-
cific antibodies. Antibodies were diluted according to the manu-
facturer’s recommendations. Alkaline phosphatase activity was
revealed with 0.15 g per mL 5-bromo-4-chloro-3-indolyl phosphate
and 0.3 mg per mL nitro blue tetrazolium (Sigma, St Louis, Mis-
souri).
ELISA testing was used to accurately quantify the amount of
HSP70 generated and secreted by melanocytes and fibroblasts
in response to 4-TBP exposure. ELISA kits were purchased from
Stressgen to measure HSP70 content of cell homogenates and
conditioned cell supernatants according to the manufacturer’ in-
structions. Briefly, experimental samples or different protein con-
centrations of recombinant HSP70 were added to wells of a 96-
well plate pre-coated with a monoclonal antibody to inducible
HSP70. After removal of the samples, the washed plate was in-
cubated with biotinylated polyclonal antibody to inducible HSP70
followed by peroxidase-conjugated avidin, and tetramethylbenzi-
dine was used as a substrate for peroxidase. Peroxidase activity
was measured at 450 nm in an EL312E microplate reader (Bio-
Tech Instruments, Winooski, Vermont). HSP70 content of individual
samples was calculated from the HSP70 standard curve.
Cytoprotection following adenoviral HSP overexpression Cells
were incubated with 107 pfu of adenovirus encoding HSP27,
HSP70, or neither (mock virus) per 106 melanocytes in 2% FBS in
M154 for 2 h at 371C in a humidified 5% CO2 incubator. The
adenovirus-containing medium was removed and replaced with
M154 and HMGS, and cells were left to express the adenoviral
genes for 48 h prior to testing. Overexpression of HSP by this
treatment was assessed by western blotting as described above.
The cytoprotective effect of stress protein overexpression was
measured by viability assays following 3 d of 4-TBP exposure by
counting the percentage of trypan blue-excluding cells.
Cytotoxicity assessment For quantitative measurements of DC
cytotoxicity, just another method (JAM) assays were used (Mat-
zinger, 1991). Briefly, target cells were pre-labeled with 3H-thymi-
dine at 1 mCi per 10,000 cells for 16 h. Immature or activated DC
were added to target cells, and DC-mediated cytotoxicity was
measured 72 h after adding DC to the labeled target cells by
comparing radioactivity retained by viable cells among individual
sample wells. In some experiments, cytotoxicity was measured
following exposure of target cells to apoptosis-inducing molecules.
Alternatively, target cells were labeled with 5 mCi/well of 51Cr (so-
dium chromate) (Amersham Biotechnologies, Quebec, Canada),
and cytotoxicity was measured as g radiation released into the
supernatant by dying cells. The latter method was replaced by
JAM assays where long incubation times led to high background
counts as a result of spontaneous chromium release.
Expression of TNF family molecules and their receptors Ex-
pression of TNF, TRAIL, and FasL on the cell surface of adherent
monocyte-derived human DC was assessed by FACS analysis.
Similarly, FACS staining was used to probe target melanocytes for
expression of TNFR1 and TNFR2, TRAILR1 and TRAILR2 and de-
coy receptors 3 and 4, and Fas. Primary antibodies reactive with
human antigens include M-301 to TNF (Endogen, Woburn, Mas-
sachusetts), rabbit polyclonal antiserum to TRAIL (Calbiochem,
San Diego, California), NOK-1 mouse monoclonal antibody to FasL
(Caltag, Burlingame, California), MAB225 mouse monoclonal an-
tibody to TNFR1 (R&D Systems), MAB226 mouse monoclonal
antibody to TNFR2 (R&D Systems), mouse monoclonal antibody
32A1380 to TRAILR1 (Imgenex, San Diego, California), mouse
monoclonal antibody 54B1005 to TRAILR2 (Imgenex), rabbit
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polyclonal antiserum to TRAILR3 (Orbigen, San Diego, California),
goat polyclonal antiserum to TRAILR4 (R&D Systems), and
MAB142 mouse monoclonal antibody to Fas (R&D Systems) at
empirically determined concentrations within the range provided
by the manufacturer. Membrane expression was assessed by in-
direct immunostaining of scraped cells, using biotinylated species-
specific secondary Abs and phycoerythrin-labeled streptavidin as
a fluorescent label. The mean fluorescence intensities and per-
centage of stained cells among at least 5000 cells were measured
by a FACSCalibur benchtop flow cytometer (BD Biosciences, San
Jose, California) equipped with a 15 mW argon–ion laser for de-
tection of fluorescence plus right and forward angle scatter, using
CellQuest software to control data acquisition.
TRAIL-mediated killing of immortalized melanocytes PIG1 cells
were plated at 10,000 cells per well in a 96-well plate, labeled with
3H-thymidine at 1 mCi/well for 16 h, and subsequently exposed to
recombinant human soluble killer TRAIL (AxxoraLLC, San Diego,
California) at 200 ng per mL, RIK-2 antibody to TRAIL (eBioSci-
ence, San Diego, California) at 5 mg per mL, and DC activated by
IFN-g pre-treatment (1000 U per mL for 48 h), or combinations
thereof. Cell viability was measured after 72 h as described under
‘‘cytotoxicity assessment’’.
Immunohistology of DC in vitiligo Four millimeter biopsies were
obtained from non-lesional and perilesional skin of four patients
with progressive vitiligo. Participants gave their written informed
consent; the study was conducted according to the Declaration of
Helsinki principles and the Institutional Review Board of Loyola
University Medical Center approved all described studies. The
abundance of DC among the skin samples was assessed by
immunohistology. Frozen sections fixed in cold acetone were ex-
posed to primary antibodies MAB1971 to CD11c (Chemicon,
Temecula, California) and 4C4.9 to S100 (Cell Marque Corporation,
Austin, Texas) reactive with human DC. The number of CD11cþper
mm of epidermal length was quantified in three skin sections from
each biopsy. The presence or absence of melanocytes was con-
firmed using antibodies NKI-Beteb to human gp100 (Caltag) and
M2-9E3 to human MART-1 (NeoMarkers, Fremont, California). Ex-
pression of TNF, TRAIL, and FasL as well as its receptors was
assessed using antibodies described above under FACS analysis
except for MAB687 to human TRAIL (R&D Systems). Single and
double stainings were completed as previously described (Le Poole
et al, 1996). Briefly, in single immunostainings, incubation with the
primary antibody was followed up with biotinylated rabbit anti-
mouse antiserum (Dakopatts, Glostrup, Denmark) and peroxidase-
labeled streptavidin (Dakopatts) diluted according to the manufac-
turers’ recommendations. In double stainings, enzyme-labeled
isotype-specific secondary antibodies (Southern Biotechnology
Associates, Birmingham, Alabama) were combined to react with
the primary antibodies of interest. Alkaline phosphatase activity
was detected using Fast Blue BB (Sigma) as a substrate, and AEC
(Sigma) was used as the substrate for peroxidase.
Statistical analysis t Tests were used for a posteriori compari-
sons among experimental results to control values. Sample sizes
for each comparison are as indicated in the figure legends.
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